Ascendiant Capital Maintains Buy on Surgepays, Lowers Price Target to $9.5
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital analyst Edward Woo maintains a Buy rating on Surgepays (NASDAQ:SURG) but lowers the price target from $10 to $9.5.

June 06, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendiant Capital analyst Edward Woo maintains a Buy rating on Surgepays but lowers the price target from $10 to $9.5.
The Buy rating suggests continued confidence in Surgepays' performance, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100